Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Recommendations
Amag Pharmaceuticals price target raised to $14 from $10 at H.C. Wainwright » 11:06
08/06/20
08/06
11:06
08/06/20
11:06
AMAG

Amag Pharmaceuticals

$10.11 /

-0.26 (-2.51%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Douglas Tsao raised the firm's price target on Amag Pharmaceuticals to $14 from $10 and keeps a Buy rating on the shares. While the company reported a "mixed" quarter, "all signs point to a turnaround" and the company is now guiding to EBITDA profitability in the second half, said Tsao. The analyst has been impressed by the speed with which CEO Scott Myers has been able to implement change and likes the renewed focus on driving Feraheme into new indications and developing ciraparantag, Tsao added.

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$10.11 /

-0.26 (-2.51%)

AMAG Amag Pharmaceuticals
$10.11 /

-0.26 (-2.51%)

08/06/20 Piper Sandler
Piper says avoid Amag as turnaround remains 'tall order'
07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
AMAG Amag Pharmaceuticals
$10.11 /

-0.26 (-2.51%)

AMAG Amag Pharmaceuticals
$10.11 /

-0.26 (-2.51%)

Recommendations
Piper says avoid Amag as turnaround remains 'tall order' » 10:38
08/06/20
08/06
10:38
08/06/20
10:38
AMAG

Amag Pharmaceuticals

$10.17 /

-0.2 (-1.93%)

Piper Sandler analyst…

Piper Sandler analyst Christoper Raymond raised the firm's price target on Amag Pharmaceuticals to $8 from $7 and keeps an Underweight rating on the shares. The analyst left the company's Q2 earnings call "feeling incrementally positive" about CEO Scott Myers. However, with Makena still facing a potential market withdrawal, Feraheme disproportionately impacted by COVID-19, a "relatively important" pipeline failure with AMAG-423 for preeclampsia, and disclosed accounting errors around historical Makena revenue reporting, Amge's turnaround "remains a tall order, especially with a sizeable convert coming due in 2022," Raymond tells investors in a research note titled "Love The New Approach But Sins of the Past Have Dug a Big Hole." As such, the analyst continues to urge investors to avoid the stock.

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

Hot Stocks
Amag finds 'immaterial errors' in Makena revenue from 2016 to 2020 » 10:37
08/06/20
08/06
10:37
08/06/20
10:37
AMAG

Amag Pharmaceuticals

$10.17 /

-0.2 (-1.93%)

Amag Pharmaceuticals said…

Amag Pharmaceuticals said earlier in its earnings release, "The financial figures and statements referenced herein have been adjusted to correct immaterial errors in Makena revenue in the historical periods 2016 through the first quarter of 2020; in aggregate, Makena revenue is reduced by $6.3 million over the four-year period. This error was identified by the company during the second quarter of 2020 and relates to the timely accrual of certain governmental rebates. The company and our independent auditors are still reviewing the prior period financial statements and the potential impact on our internal controls over financial reporting for the periods. Therefore, the financials set forth in this release are preliminary and may be updated in the company's quarterly report on Form 10Q for the quarter ended June 30, 2020. As a result, investors are cautioned not to place undue reliance on these financial statements."

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

AMAG Amag Pharmaceuticals
$10.17 /

-0.2 (-1.93%)

Hot Stocks
Amag stops AMAG-423 study in preeclampsia after DSMB recommendation » 10:35
08/06/20
08/06
10:35
08/06/20
10:35
AMAG

Amag Pharmaceuticals

$10.04 /

-0.33 (-3.18%)

Amag Pharmaceuticals…

Amag Pharmaceuticals announced this morning that following an analysis, the Data and Safety Monitoring Board provided a unanimous recommendation to stop the AMAG-423 Phase 2b/3a study, based upon the low likelihood that future enrollment would demonstrate a benefit in women with severe preeclampsia. Amag has accepted the DSMB's recommendation to stop the study "and is currently focused on ensuring an appropriate closeout of the study in partnership with investigators and other relevant stakeholders."

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$10.04 /

-0.33 (-3.18%)

AMAG Amag Pharmaceuticals
$10.04 /

-0.33 (-3.18%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
AMAG Amag Pharmaceuticals
$10.04 /

-0.33 (-3.18%)

AMAG Amag Pharmaceuticals
$10.04 /

-0.33 (-3.18%)

Earnings
Amag Pharmaceuticals sees FY20 revenue view $225M-$255M, consensus $250.01M » 07:09
08/06/20
08/06
07:09
08/06/20
07:09
AMAG

Amag Pharmaceuticals

$10.37 /

+0.37 (+3.70%)

"Strong execution…

"Strong execution across our portfolio throughout the COVID-19 pandemic allows us to reissue financial guidance that reflects the relative stability of Makena over the quarter and the momentum that Feraheme began to build in June, which saw record highs in monthly share and ex-factory volume," said Brian Piekos, Chief Financial Officer. "The guidance we are sharing today is designed to prioritize investments that will drive long-term growth while also putting us on track to return to positive adjusted EBITDA."

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

Earnings
Amag Pharmaceuticals reports Q2 EPS (39c), consensus (19c) » 07:08
08/06/20
08/06
07:08
08/06/20
07:08
AMAG

Amag Pharmaceuticals

$10.37 /

+0.37 (+3.70%)

Reports Q2 revenue…

Reports Q2 revenue $52.8M, consensus $57.95M. "Amidst the unprecedented uncertainty that COVID-19 placed on the healthcare system and our economy, AMAG's marketed therapeutics performed well in the second quarter due in part to our teams' ability to adapt in a rapidly-changing environment," said Scott Myers, AMAG's Chief Executive Officer. "Over the past three months, we have advanced the company's strategic evolution by reaching important milestones that include a strategic, ex-US partnership with Norgine to further progress ciraparantag and strengthen our company's ability to invest in our pipeline. We have also streamlined expenses by completing the divestment of Intrarosa and Vyleesi and making changes to our portfolio designed to further focus on programs with the highest potential to deliver innovative treatments for patients and unlock shareholder value."

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

AMAG Amag Pharmaceuticals
$10.37 /

+0.37 (+3.70%)

Wednesday
Hot Stocks
Palatin completes enrollment in Phase 2 Study with PL9643 » 07:36
08/05/20
08/05
07:36
08/05/20
07:36
PTN

Palatin

$0.58 /

-0.0044 (-0.75%)

Palatin Technologies…

Palatin Technologies announced completion of enrollment of its Phase 2 study with PL9643 for the treatment of dry eye disease. After delaying enrollment of new patient groups due to the COVID-19 pandemic, Palatin reinitiated enrollment in its PL9643 Phase 2 clinical study in subjects with dry eye disease last month. With enrollment completed, data readout is targeted for the fourth quarter of calendar year 2020.

ShowHide Related Items >><<
PTN Palatin
$0.58 /

-0.0044 (-0.75%)

PTN Palatin
$0.58 /

-0.0044 (-0.75%)

07/27/20 H.C. Wainwright
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright
01/10/20 H.C. Wainwright
Palatin price target lowered to $2 from $7.50 at H.C. Wainwright
PTN Palatin
$0.58 /

-0.0044 (-0.75%)

Over a week ago
Recommendations
Agreement termination 'optimal' for Vyleesi future, says H.C. Wainwright » 10:16
07/27/20
07/27
10:16
07/27/20
10:16
PTN

Palatin

$0.61 /

+0.0439 (+7.82%)

, AMAG

Amag Pharmaceuticals

$9.70 /

-0.3 (-3.00%)

, PFE

Pfizer

$37.62 /

-0.05 (-0.13%)

, ABBV

AbbVie

$96.97 /

+0.01 (+0.01%)

, MRK

Merck

$78.15 /

+1.04 (+1.35%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Joseph Pantginis notes that Palatin (PTN) and Amag Pharmaceuticals (AMAG) announced the mutual termination of the license agreement for Vyleesi in North America, with Palatin retaining all North American and development and commercialization rights. The analyst believes that a major point for investors to focus on is that Amag's launch of the drug was essentially aborted because of its change of strategy before a market for Vyleesi could be established. The launch was still in the early stages of broad sampling. Instead of Amag licensing Vyleesi to someone else, Pantginis believes this is the optimal next step for the drug's future, as it gives Palatin important freedom to operate now, including finding the best potential partnership possible. Management indicated that all options are now on the table, which could range from North America again to broader geographic deals, he adds. Pantginis believes that Pfizer (PFE), AbbVie (ABBV), and Merck (MRK) could be relevant targets for partnering. Further, it would be surprising to him if Palatin had not already begun discussions with these companies prior to partnering with Amag. He has a Buy rating and a price target of $2 on Palatin's shares.

ShowHide Related Items >><<
PTN Palatin
$0.61 /

+0.0439 (+7.82%)

PFE Pfizer
$37.62 /

-0.05 (-0.13%)

MRK Merck
$78.15 /

+1.04 (+1.35%)

AMAG Amag Pharmaceuticals
$9.70 /

-0.3 (-3.00%)

ABBV AbbVie
$96.97 /

+0.01 (+0.01%)

PTN Palatin
$0.61 /

+0.0439 (+7.82%)

01/10/20 H.C. Wainwright
Palatin price target lowered to $2 from $7.50 at H.C. Wainwright
AMAG Amag Pharmaceuticals
$9.70 /

-0.3 (-3.00%)

05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
03/04/20 Piper Sandler
Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler
PFE Pfizer
$37.62 /

-0.05 (-0.13%)

07/20/20 Jefferies
AstraZeneca slide 'overdone' after 'encouraging' vaccine data, says Jefferies
07/14/20 Mizuho
IPR not likely to impact uniQure's ability to commercialize AMT-061, says Mizuho
07/13/20 Canaccord
BioNTech price target raised to $75 from $60 at Canaccord
07/08/20 Piper Sandler
Opko Health price target raised to $6 from $4 at Piper Sandler
ABBV AbbVie
$96.97 /

+0.01 (+0.01%)

07/07/20 Truist
Evolus price target lowered to $6 from $12 at SunTrust
07/06/20 Piper Sandler
Biohaven launch of Nurtec 'continues to impress,' says Piper Sandler
06/29/20 Mizuho
AbbVie price target raised to $110 from $101 at Mizuho
06/26/20 Raymond James
Adverum Biotechnologies downgradedat Raymond James on abicipar CRL
MRK Merck
$78.15 /

+1.04 (+1.35%)

06/30/20 SVB Leerink
Seattle Genetics price target raised to $167 from $155 at SVB Leerink
06/30/20 Oppenheimer
Seattle Genetics price target raised to $210 from $200 at Oppenheimer
06/25/20 Lake Street
Lake Street says Keytruda approval improves outlook for Checkpoint's cosibelimab
06/23/20 Maxim
Inovio price target raised to $24 from $18 at Maxim
PTN Palatin
$0.61 /

+0.0439 (+7.82%)

PFE Pfizer
$37.62 /

-0.05 (-0.13%)

MRK Merck
$78.15 /

+1.04 (+1.35%)

AMAG Amag Pharmaceuticals
$9.70 /

-0.3 (-3.00%)

ABBV AbbVie
$96.97 /

+0.01 (+0.01%)

PFE Pfizer
$37.62 /

-0.05 (-0.13%)

MRK Merck
$78.15 /

+1.04 (+1.35%)

ABBV AbbVie
$96.97 /

+0.01 (+0.01%)

PFE Pfizer
$37.62 /

-0.05 (-0.13%)

MRK Merck
$78.15 /

+1.04 (+1.35%)

AMAG Amag Pharmaceuticals
$9.70 /

-0.3 (-3.00%)

ABBV AbbVie
$96.97 /

+0.01 (+0.01%)

PFE Pfizer
$37.62 /

-0.05 (-0.13%)

MRK Merck
$78.15 /

+1.04 (+1.35%)

ABBV AbbVie
$96.97 /

+0.01 (+0.01%)

Hot Stocks
Amag Pharmaceuticals, Palatin mutually terminate 2017 license agreement » 07:39
07/27/20
07/27
07:39
07/27/20
07:39
AMAG

Amag Pharmaceuticals

$10.00 /

-0.09 (-0.89%)

AMAG Pharmaceuticals…

AMAG Pharmaceuticals announced AMAG and Palatin Technologies have mutually terminated the January 2017 license agreement pursuant to which AMAG was granted exclusive rights to develop and commercialize Vyleesi, a melanocortin receptor agonist indicated for the treatment of acquired, generalized hypoactive sexual desire disorder in premenopausal women, in North America. Under the terms of the termination agreement, all of AMAG's rights and obligations to develop and commercialize Vyleesi under the license agreement will terminate, and full ownership of Vyleesi will transfer back to Palatin. AMAG will pay Palatin $12M at closing and $4.3M on March 31, 2021. In exchange for such payments, Palatin will assume all Vyleesi manufacturing agreements and associated minimum commitments and AMAG will transfer to Palatin all data and assets related exclusively to Vyleesi. Under the agreement, Palatin has agreed to compensate AMAG to provide certain transitional services to Palatin for a period of time to ensure continued patient access to Vyleesi during the transition back to Palatin.

ShowHide Related Items >><<
AMAG Amag Pharmaceuticals
$10.00 /

-0.09 (-0.89%)

AMAG Amag Pharmaceuticals
$10.00 /

-0.09 (-0.89%)

05/12/20 H.C. Wainwright
Amag Pharmaceuticals price target raised to $10 from $9 at H.C. Wainwright
05/11/20 Piper Sandler
Amag shares to continue to see pressure from headwinds, says Piper Sandler
04/17/20 H.C. Wainwright
Amag Pharmaceuticals price target lowered to $9 from $12 at H.C. Wainwright
03/04/20 Piper Sandler
Amag Pharmaceuticals price target lowered to $7 from $9 at Piper Sandler
AMAG Amag Pharmaceuticals
$10.00 /

-0.09 (-0.89%)

AMAG Amag Pharmaceuticals
$10.00 /

-0.09 (-0.89%)

Hot Stocks
Palatin and AMAG terminate license agreement for Vyleesi » 07:02
07/27/20
07/27
07:02
07/27/20
07:02
PTN

Palatin

$0.56 /

-0.0024 (-0.43%)

Palatin Technologies…

Palatin Technologies announced that it has mutually terminated the January 2017 license agreement which granted AMAG Pharmaceuticals exclusive North American rights to market Vyleesi, the first and only on demand treatment for pre-menopausal women suffering from acquired, generalized, hypoactive sexual desire disorder (HSDD), a condition affecting one in ten premenopausal women. Under the terms of the termination agreement, Palatin will regain all North American development and commercialization rights for Vyleesi. AMAG will make a $12M payment to Palatin at closing and a $4.3M million payment to Palatin on March 31, 2021. Palatin will assume all Vyleesi manufacturing agreements, and AMAG will transfer all information, data, and assets related exclusively to Vyleesi, including, but not limited to, existing inventory. AMAG will provide certain transitional services to Palatin for a period of time to ensure continued patient access to Vyleesi during the transition back to Palatin. Palatin will reimburse AMAG for the costs of the transition services.

ShowHide Related Items >><<
PTN Palatin
$0.56 /

-0.0024 (-0.43%)

PTN Palatin
$0.56 /

-0.0024 (-0.43%)

01/10/20 H.C. Wainwright
Palatin price target lowered to $2 from $7.50 at H.C. Wainwright
PTN Palatin
$0.56 /

-0.0024 (-0.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.